The CD4+/CD8+ ratio was higher in the GPR87 high-expression group than the low GPR87 expression group, suggesting that the high-expression group patients were correspondingly poorer for non-small cell lung cancer immunotherapy, consistent with the results of the TIDE algorithm analysis. Here, CD8A is linked to non-small cell lung carcinoma.